Gateway Investment Advisers LLC Increases Position in Henry Schein, Inc. $HSIC

Gateway Investment Advisers LLC increased its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 214.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 12,091 shares of the company’s stock after acquiring an additional 8,243 shares during the quarter. Gateway Investment Advisers LLC’s holdings in Henry Schein were worth $1,010,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Blackhawk Capital Partners LLC raised its position in shares of Henry Schein by 95.1% in the 2nd quarter. Blackhawk Capital Partners LLC now owns 9,101 shares of the company’s stock valued at $760,000 after purchasing an additional 4,436 shares in the last quarter. GHP Investment Advisors Inc. grew its position in shares of Henry Schein by 1.5% during the second quarter. GHP Investment Advisors Inc. now owns 52,611 shares of the company’s stock worth $4,394,000 after buying an additional 798 shares in the last quarter. Canvas Wealth Advisors LLC acquired a new stake in shares of Henry Schein during the second quarter worth approximately $201,000. Contravisory Investment Management Inc. bought a new stake in shares of Henry Schein in the second quarter worth $84,000. Finally, Breakwater Capital Group acquired a new stake in Henry Schein in the second quarter valued at $200,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Robert W. Baird set a $97.00 price objective on shares of Henry Schein in a research note on Wednesday, May 6th. Morgan Stanley reissued an “underweight” rating and issued a $64.00 target price (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. BTIG Research restated a “buy” rating and issued a $100.00 target price on shares of Henry Schein in a research note on Wednesday, August 5th. Mizuho reduced their price target on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Finally, BMO Capital Markets started coverage on Henry Schein in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $85.00 price target for the company. Eight research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $92.27.

Henry Schein Stock Performance

Henry Schein stock opened at $90.74 on Thursday. The company has a market cap of $10.11 billion, a PE ratio of 26.45, a P/E/G ratio of 1.70 and a beta of 0.80. The company has a fifty day moving average price of $84.28 and a two-hundred day moving average price of $78.89. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.32 and a quick ratio of 0.73. Henry Schein, Inc. has a 12 month low of $61.94 and a 12 month high of $92.18.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, topping analysts’ consensus estimates of $1.24 by $0.03. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The company had revenue of $3.46 billion for the quarter, compared to analysts’ expectations of $3.37 billion. During the same period in the prior year, the company earned $1.10 earnings per share. The firm’s revenue was up 6.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. Research analysts expect that Henry Schein, Inc. will post 5.35 earnings per share for the current year.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.